Rigel to Present at the Jefferies Global Healthcare Conference
Rigel Pharmaceuticals (Nasdaq: RIGL), a commercial stage biotechnology company specializing in hematologic disorders and cancer treatments, has announced its participation in the upcoming Jefferies Global Healthcare Conference. CEO Raul Rodriguez will deliver a company overview on June 4, 2025, at 12:50 p.m. ET in New York. The presentation will be accessible via live webcast through Rigel's Investor Relations website.
Founded in 1996 and headquartered in South San Francisco, Rigel focuses on developing novel therapies for patients with blood disorders and cancer. Interested parties can access the presentation through www.rigel.com.
Rigel Pharmaceuticals (Nasdaq: RIGL), un'azienda biotecnologica in fase commerciale specializzata in disturbi ematologici e trattamenti oncologici, ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference. Il CEO Raul Rodriguez presenterà una panoramica aziendale il 4 giugno 2025 alle 12:50 ET a New York. La presentazione sarà disponibile in diretta streaming sul sito delle Relazioni con gli Investitori di Rigel.
Fondata nel 1996 e con sede a South San Francisco, Rigel si dedica allo sviluppo di terapie innovative per pazienti con malattie del sangue e cancro. Gli interessati potranno seguire la presentazione su www.rigel.com.
Rigel Pharmaceuticals (Nasdaq: RIGL), una empresa biotecnológica en etapa comercial especializada en trastornos hematológicos y tratamientos contra el cáncer, ha anunciado su participación en la próxima Jefferies Global Healthcare Conference. El CEO Raul Rodriguez ofrecerá una visión general de la empresa el 4 de junio de 2025 a las 12:50 p.m. ET en Nueva York. La presentación estará disponible en transmisión en vivo a través del sitio web de Relaciones con Inversionistas de Rigel.
Fundada en 1996 y con sede en South San Francisco, Rigel se enfoca en desarrollar terapias novedosas para pacientes con trastornos sanguíneos y cáncer. Los interesados podrán acceder a la presentación en www.rigel.com.
Rigel Pharmaceuticals (나스닥: RIGL)은 혈액 질환 및 암 치료를 전문으로 하는 상업 단계의 생명공학 회사로, 다가오는 Jefferies Global Healthcare Conference에 참여할 것임을 발표했습니다. CEO Raul Rodriguez는 2025년 6월 4일 오후 12시 50분(동부시간) 뉴욕에서 회사 개요를 발표할 예정입니다. 발표는 Rigel 투자자 관계 웹사이트를 통해 생중계로 시청할 수 있습니다.
1996년에 설립되어 사우스 샌프란시스코에 본사를 둔 Rigel은 혈액 질환 및 암 환자를 위한 혁신적인 치료법 개발에 집중하고 있습니다. 관심 있는 분들은 www.rigel.com에서 발표를 시청할 수 있습니다.
Rigel Pharmaceuticals (Nasdaq : RIGL), une société biotechnologique en phase commerciale spécialisée dans les troubles hématologiques et les traitements contre le cancer, a annoncé sa participation à la prochaine Jefferies Global Healthcare Conference. Le PDG Raul Rodriguez présentera un aperçu de l'entreprise le 4 juin 2025 à 12h50 ET à New York. La présentation sera accessible en direct via un webcast sur le site des relations investisseurs de Rigel.
Fondée en 1996 et basée à South San Francisco, Rigel se concentre sur le développement de thérapies innovantes pour les patients atteints de troubles sanguins et de cancer. Les intéressés pourront accéder à la présentation sur www.rigel.com.
Rigel Pharmaceuticals (Nasdaq: RIGL), ein biotechnologisches Unternehmen in der kommerziellen Phase, das sich auf hämatologische Erkrankungen und Krebstherapien spezialisiert hat, hat seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference angekündigt. CEO Raul Rodriguez wird am 4. Juni 2025 um 12:50 Uhr ET in New York einen Unternehmensüberblick präsentieren. Die Präsentation wird live über die Investor-Relations-Website von Rigel als Webcast verfügbar sein.
Das 1996 gegründete Unternehmen mit Hauptsitz in South San Francisco konzentriert sich auf die Entwicklung neuartiger Therapien für Patienten mit Blutkrankheiten und Krebs. Interessierte können die Präsentation über www.rigel.com verfolgen.
- None.
- None.
To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David Rosen
Argot Partners
646.461.6387
david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-to-present-at-the-jefferies-global-healthcare-conference-302466594.html
SOURCE Rigel Pharmaceuticals, Inc.
FAQ
When is Rigel Pharmaceuticals (RIGL) presenting at the Jefferies Global Healthcare Conference 2025?
Who will be presenting for Rigel Pharmaceuticals at the Jefferies Healthcare Conference?
How can investors access Rigel's presentation at the Jefferies Conference?
What is Rigel Pharmaceuticals' (RIGL) main business focus?
